Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology. (TEMPO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01292551
Recruitment Status : Completed
First Posted : February 9, 2011
Last Update Posted : April 19, 2013
Aarhus University Hospital
Bispebjerg Hospital
Information provided by (Responsible Party):
Anders Hebert, Rigshospitalet, Denmark

February 8, 2011
February 9, 2011
April 19, 2013
February 2011
March 2013   (Final data collection date for primary outcome measure)
Change from baseline in VO2max at 14 weeks [ Time Frame: Baseline and 14 weeks ]
Maximal O2 uptake in ml/min/kg in ergometer bicycle test
Same as current
Complete list of historical versions of study NCT01292551 on Archive Site
  • Change from baseline in blood samples at 14 weeks [ Time Frame: Baseline and 14 weeks ]
    blood samples measured: plasma CT pro endothelin-1, IgG, IgA, NT pro BNP, albumin, free protein
  • Change from baseline in SF36 questionnaire score at 14 weeks [ Time Frame: Baseline and 14 weeks ]
    SF36 quality of life interview
  • Change from baseline in feces alfa 1 antitrypsin at 14 weeks [ Time Frame: Baseline and 14 weeks ]
    Fecal alfa 1 antitrypsin in mg/g
  • Number of participants with adverse events [ Time Frame: 2, 6, 10 and 14 weeks after start of treatment ]
    general interview on adverse effects, and questions with special focus on typical adverse effects in Bosentan
  • Change from baseline in vital signs [ Time Frame: Baseline, 2, 6, 10 and 14 weeks ]
    Systemic bloodpressure in mmHg, Pulse in min-1, Oxygen saturation in percent
  • Change from baseline in control blood samples [ Time Frame: Baseline, 2, 6, 10 and 14 weeks ]
    Liver and renal biomarkers, Hb, PCV, trc and hCG for women
  • Change from baseline in cardiac output/pulmonary blood flow [ Time Frame: Baseline and 14 weeks ]
    CO measured by Stringer Wassermann method during ergometer bicycle test
Same as current
Not Provided
Not Provided
Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology.
Treatment With Endothelin Antagonist to Tcpc Patients; a Multicenter, Randomized, Prospective Study Measuring Maximal O2 Uptake in Ergometer Bicycle Test

The purpose of this study is to determine whether Bosentan is an effective and safe treatment to adolescent and adult (15 years and older) patients, born with one ventricle of the heart instead of two (single ventricle physiology) and who have undergone TCPC as a palliative surgical treatment. The aim of the TCPC operation is to use the one functioning ventricle to pump the blood flow to the body, while the blood to the lungs is received directly from the caval veins, and is thus a passive flow, without the aid of a ventricle to actively pump the blood through the pulmonary circulation. The resistance in the pulmonary circulation is therefore critical to these patients. These patients have markedly lower work capacity in bicycle test than the general public. Furthermore they have a high risk of developing complications e.g. loss of protein from the intestines.

Bosentan is a medication that lowers the resistance in the pulmonary circulation. It is routinely used for patients with pulmonary hypertension. Some studies have shown that drugs that lower the pulmonary resistance can increase exercise capacity significantly in patients with single ventricle physiology.

In this study 80 patients will receive either placebo or Bosentan for 14 weeks. Before and after the treatment, bicycle test along with blood samples, stool samples and quality of life interviews will be performed. Every four weeks during the study blood samples, physical exam and interviews will be performed to ensure the safety of the treatment.

The investigators expect to find a significant increase in work capacity after 14 weeks in the treatment group compared with the placebo group.

Moreover the investigators hope to find a decrease in intestinal protein loss and an improved quality of life.

In the statistical analysis the investigators wish to analyse interactions between the primary endpoint and predefined subgroups in order to distinguish responders from non-responders to the treatment. The predefined subgroups are:

NT-proBNP > 100 (yes/no) Ventricular anatomy (RV/LV) CT-proEndothelin-1. In the latter, the investigators do not wish to predefine a specific value, due to limited experience with this analysis. We wish to use the data from the study to find a cut-off value, that is able to predict positive response to treatment.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
  • Hypoplastic Left Heart Syndrome
  • Tricuspid Atresia
  • Other Specified Congenital Anomalies of Heart
  • Drug: Bosentan
    tablets Bosentan 62,5 mg x 2 daily for two weeks, then 125 mg x 2 daily for 12 weeks
    Other Name: Bosentan: Tracleer
  • Drug: Placebo
    Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks
  • Active Comparator: Bosentan
    Intervention: Drug: Bosentan
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2013
March 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • TCPC operated
  • Age > 15 years old
  • Clinical stability > 3 months, evaluated by investigator from clinical record
  • For women: Negative s-hCG and use of contraception

Exclusion Criteria:

  • Severe heart failure (NYHA-class IV)
  • Oxygen saturation < 85 % at rest
  • Pre-existing liver condition (transaminases 2x > reference)
  • Renal failure (creatinin > 150 mmol/l)
  • Obstruction of TCPC circulation
  • History of work induced severe arrhythmia
  • Systolic blood pressure below 80% of reference (BT < 88 mmHg)
  • Use of any of following drugs: Fluconazol, Ketoconazole, CiclosporinA, Lopinavir, Ritonavir, Rifampicin, Carbamazepin and Phenytoin
  • Significant extra-cardiac condition e.g. neurological impairment
Sexes Eligible for Study: All
15 Years and older   (Child, Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Denmark,   Sweden
TEMPO study
2010-022389-28 ( EudraCT Number )
Not Provided
Not Provided
Anders Hebert, Rigshospitalet, Denmark
Rigshospitalet, Denmark
  • Aarhus University Hospital
  • Bispebjerg Hospital
  • Actelion
Study Director: Lars Sondergaard, DMSc Rigshospitalet, Denmark
Principal Investigator: Anders H Hebert, MD Rigshospitalet, Denmark
Rigshospitalet, Denmark
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP